|Articles|January 30, 2018
FDA clears new drug application for topical psoriasis treatment
Listen
0:00 / 0:00
Key Takeaways
- IDP-118 lotion combines halobetasol propionate and tazarotene for plaque psoriasis treatment in adults.
- If approved, it would be the first formulation to combine these agents for psoriasis.
The Food and Drug Administration accepted a new drug application for IDP-118 lotion (halobetasol propionate and tazarotene, Ortho Dermatologics), for the topical treatment of plaque psoriasis.
Advertisement
The Food and Drug Administration accepted a new drug application for IDP-118 lotion (halobetasol propionate and tazarotene, Ortho Dermatologics), for the topical treatment of plaque psoriasis.
The lotion, if approved, would be the first of its kind to combine tazarotene and halobetasol propionate in a single formulation for psoriasis in adult patients, according to the company, which is a division of Valeant.
In initial trials, the most common adverse events were application site pain (2.6 percent) and contact dermatitis (7.4 percent).
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
2
Dual-Action Microneedle Patch Shows Promise for Psoriasis in Preclinical Study
3
AI Analysis Reveals Menopausal Hair Loss Linked to Systemic Health and Inflammation
4
The Misuse and Overuse of the Word “Robust” in Dermatology
5